Ceftrex Dosage/Direction for Use

Direction for use: Intramuscular injection: CEFTREX 0.25 g is dissolved in 2 ml of 1% lidocaine solution and administered by deep intragluteal injection. It is recommended that not more than 1 g be injected on either side. *The lidocaine solution must never be administered intravenously.
Intravenous injection: CEFTREX 0.5 g is dissolved in 5 ml, and 1 g in 10 ml of sterile water for injection and then administered by IV injection lasting two to four minutes.
Intravenous infusion: The infusion should last at least 30 minutes. 2 g of CEFTREX is dissolved in 40 ml of one of the following calcium-free infusion solutions: sodium chloride 0.9%, sodium chloride 0.45% + dextrose 2.5%, dextrose 5%, dextrose 10%, dextran 6% in 5% dextrose, sterile water for injection.
Standard dosage: Adults and children over 12 years: Administered 1-2 g once daily (every 24 hours).
In severe cases the dosage may be raised to a maximum dose of 4 g administered once daily.
Infants and children (three weeks to 12 years): 20-80 mg/kg body weight administered once daily.
Neonates (up to two weeks): 20-50 mg/kg body weight, administered once daily (not exceed 50 mg/kg/day).
Elderly: The dosages recommended for adults require no modification in geriatric patients.
Special dosage: In bacterial meningitis in infants and children, treatment begins with doses of 100 mg/kg body weight (not to exceed 4 g) once daily. As soon as the causative organism has been identified and its sensitivity determined, the dosage can be reduced accordingly.
The duration of therapy is as the following: Neisseria meningitidis 4 days; Streptococcus pneumoniae 7 days; Haemophilus influenzae 6 days.
For the treatment of Gonorrhea: a single IM dose of 250 mg is advised.
Impaired Renal and Hepatic Function: In patients with impaired renal function, there is no need to reduce the dosage provided hepatic function is intact. Only in cases of preterminal renal failure (creatinine clearance <10 mL/min) should the CEFTREX dosage not exceed 2 g daily. In patients with liver damage, there is no need to reduce the dosage provided renal function is intact. In patients with both severe renal and hepatic dysfunction, the plasma concentrations of ceftriaxone should be determined at regular intervals and if necessary, the dose should be adjusted.
In patients undergoing dialysis, no additional supplementary dosing is required following dialysis. Plasma concentrations should be monitored, however, to determine whether dosage adjustments are necessary, since the elimination rate in these patients may be altered.